Latest:
Dr. Mitri Discusses the Promise of Trastuzumab Biosimilars
Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Zev A. Wainberg, MD
Latest:
Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer
Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.
Zhi Zhang Yang, MD
Latest:
Dr. Yang on the Efficacy of Immunotherapy in Follicular Lymphoma
Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.
Zofia Piotrowska, MD, Massachusetts General Hospital Cancer Center
Latest:
Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs
Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.
Zofia Piotrowska, MD, MHS
Latest:
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.